Re-evaluating the survival benefit of adding camrelizumab to TACE plus tyrosine-kinase inhibitors in unresectable hepatocellular carcinoma: the undervalued influence of TACE frequency.

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Annals of hepatology Pub Date : 2025-09-26 DOI:10.1016/j.aohep.2025.102126

Longshuang Wang, Jian Zhang, Jianfei Liu

引用次数: 0

查看原文本刊更多论文

重新评估camrelizumab联合TACE +酪氨酸激酶抑制剂治疗不可切除肝癌的生存获益：TACE频率的低估影响

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hepatology 医学-胃肠肝病学

CiteScore

7.90

自引率

2.60%

发文量

183

审稿时长

4-8 weeks

期刊介绍： Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.